	US 12,195,550 B2
	Targeting intracellular target-binding determinants with intracellular antibodies
Richard H. Weisbart, Sepulveda, CA (US); and Robert N. Nishimura, Sepulveda, CA (US)
Assigned to The United States of America as Represented by the Department of Veterans Affairs, Washington, DC (US)
Filed by The United States of America as Represented by the Department of Veterans Affairs, Washington, DC (US)
Filed on Jun. 15, 2020, as Appl. No. 16/902,173.
Application 15/042,106 is a division of application No. 13/844,318, filed on Mar. 15, 2013, granted, now 9,283,272, issued on Oct. 10, 2013.
Application 16/902,173 is a continuation of application No. 15/042,106, filed on Feb. 11, 2016, granted, now 10,683,363.
Claims priority of provisional application 61/618,613, filed on Mar. 30, 2012.
Prior Publication US 2022/0089771 A1, Mar. 24, 2022 Prior Publication US 2024/0052056 A9, Feb. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/3053 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01)]

2 Claims

1. A bispecific antibody comprising a first Fv fragment, wherein the first Fv fragment comprises a heavy chain variable domain comprising: a) a complementarity determining region (CDR) CDRH1 comprising SEQ ID NO: 11, b) a CDRH2 comprising SEQ ID NO: 13 and c) a CDRH3 comprising SEQ ID NO: 15; and, a light chain variable domain comprising: a) a CDRL1 comprising SEQ ID NO: 5, b) a CDRL2 comprising SEQ ID NO: 7, and c) a CDRL3 comprising SEQ ID NO: 9; and a second Fv fragment, wherein the second Fv fragment comprises a heavy chain variable domain comprising: a) a CDRH1 comprising SEQ ID NO: 23, b) CDRH2 comprising SEQ ID NO: 25 and c) CDRH3 comprising SEQ ID NO: 27; and, a light chain variable domain comprising: a) CDRL1 comprising SEQ ID NO: 17, b) CDRL2 comprising SEQ ID NO: 19, and c) CDRL3 comprising SEQ ID NO: 21.